UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
Commission File Number:
(Exact name of registrant as specified in its charter)
|
|
|
| ||
(State or other jurisdiction of incorporation or organization) |
| (IRS Employer Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip code) |
( (Registrant’s telephone number, including area code) |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
|
|
|
|
Yes |
| No | o |
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
|
|
|
|
Yes |
| No | o |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
|
|
|
|
|
|
|
|
|
|
|
x |
| Accelerated Filer | o |
| Non-accelerated Filer | o |
| Smaller Reporting Company |
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
|
|
|
|
Yes | o | No |
Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
| |
Title of Each Class | Trading Symbol | Name of Each Exchange on which Registered | Amount | Date | |
|
|
|
|
| |
March 31, 2024 | |||||
|
|
|
|
|
SUBSIDIARY COMPANIES
Index
|
|
|
|
| Page No. |
PART I. FINANCIAL INFORMATION: |
|
|
|
Item 1. Financial Statements |
|
| |
March 31, 2024 and December 31, 2023 | 3 |
|
|
| |
Three months ended March 31, 2024 and 2023 | 4 |
|
|
| |
Three months ended March 31, 2024 and 2023 | 5 |
|
|
Unaudited Consolidated Statements of Changes in Stockholders’ Equity- |
|
Three months ended March 31, 2024 and 2023 | 6 |
|
|
7 | |
|
|
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | 20 |
|
|
Item 3. Quantitative and Qualitative Disclosures about Market Risk | 30 |
|
|
30 | |
|
|
PART II. OTHER INFORMATION |
|
|
|
30 | |
|
|
30 | |
|
|
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 31 |
|
|
31 | |
|
|
31 | |
|
|
31 | |
|
|
32 | |
|
|
EX – 31.1 |
|
EX – 31.2 |
|
EX – 32.1 |
|
EX – 32.2 |
|
EX – 101 |
|
EX – 104 |
|
|
|
33 |
|
|
|
|
|
|
PART I. FINANCIAL INFORMATION | |||||
Item 1. Financial Statements | |||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||
UNAUDITED CONSOLIDATED BALANCE SHEETS | |||||
(in thousands, except share and per share data) | |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
| March 31, 2024 |
| December 31, 2023 | ||
ASSETS |
|
|
|
|
|
Current assets |
|
|
|
|
|
Cash and cash equivalents | $ | |
| $ | |
Accounts receivable less allowances |
| |
|
| |
Inventories |
| |
|
| |
Prepaid income taxes |
| |
|
| |
Prepaid expenses |
| |
|
| |
Total current assets |
| |
|
| |
Investments of deferred compensation plans held in trust |
| |
|
| |
Properties and equipment, at cost, less accumulated depreciation of $ |
| |
|
| |
Lease right of use asset |
| |
|
| |
Identifiable intangible assets less accumulated amortization of $ |
| |
|
| |
Goodwill |
| |
|
| |
Other assets |
| |
|
| |
Total Assets | $ | |
| $ | |
|
|
|
|
|
|
LIABILITIES |
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Accounts payable | $ | |
| $ | |
Income taxes |
| |
|
| |
Accrued insurance |
| |
|
| |
Accrued compensation |
| |
|
| |
Accrued legal |
| |
|
| |
Short-term lease liability |
| |
|
| |
Other current liabilities |
| |
|
| |
Total current liabilities |
| |
|
| |
Deferred income taxes |
| |
|
| |
Deferred compensation liabilities |
| |
|
| |
Long-term lease liability |
| |
|
| |
Other liabilities |
| |
|
| |
Total Liabilities |
| |
|
| |
Commitments and contingencies (Note 10) |
|
|
| ||
STOCKHOLDERS' EQUITY |
|
|
|
|
|
Capital stock - authorized |
| |
|
| |
Paid-in capital |
| |
|
| |
Retained earnings |
| |
|
| |
Treasury stock - |
| ( |
|
| ( |
Deferred compensation payable in Company stock |
| |
|
| |
Total Stockholders' Equity |
| |
|
| |
Total Liabilities and Stockholders' Equity | $ | |
| $ | |
|
|
|
|
|
|
See Accompanying Notes to Unaudited Consolidated Financial Statements. |
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME | ||||||
(in thousands, except per share data) | ||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Three Months Ended March 31, |
| ||||
| 2024 |
| 2023 |
| ||
Service revenues and sales | $ | |
| $ | |
|
Cost of services provided and goods sold (excluding depreciation) |
| |
|
| |
|
Selling, general and administrative expenses |
| |
|
| |
|
Depreciation |
| |
|
| |
|
Amortization |
| |
|
| |
|
Other operating expense |
| |
|
| |
|
Total costs and expenses |
| |
|
| |
|
Income from operations |
| |
|
| |
|
Interest expense |
| ( |
|
| ( |
|
Other income/(expense) - net |
| |
|
| ( |
|
Income before income taxes |
| |
|
| |
|
Income taxes |
| ( |
|
| ( |
|
Net income | $ | |
| $ | |
|
|
|
|
|
|
|
|
Earnings Per Share: |
|
|
|
|
|
|
Net income | $ | |
| $ | |
|
Average number of shares outstanding |
| |
|
| |
|
|
|
|
|
|
|
|
Diluted Earnings Per Share: |
|
|
|
|
|
|
Net income | $ | |
| $ | |
|
Average number of shares outstanding |
| |
|
| |
|
|
|
|
|
|
|
|
Cash Dividends Per Share | $ | |
| $ | |
|
|
|
|
|
|
|
|
See Accompanying Notes to Unaudited Consolidated Financial Statements. |
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||
(in thousands) | |||||
|
| ||||
| Three Months Ended March 31, | ||||
| 2024 |
| 2023 | ||
Cash Flows from Operating Activities |
|
|
|
|
|
Net income | $ | |
| $ | |
Adjustments to reconcile net income to net cash provided |
|
|
|
|
|
by operating activities: |
|
|
|
|
|
Depreciation and amortization |
| |
|
| |
Noncash long-term incentive compensation |
| |
|
| |
Stock option expense |
| |
|
| |
Benefit for deferred income taxes |
| ( |
|
| ( |
Amortization of debt issuance costs |
| |
|
| |
Changes in operating assets and liabilities: |
|
|
|
|
|
Decrease/(increase) in accounts receivable |
| |
|
| ( |
Decrease/(increase) in inventories |
| |
|
| ( |
Decrease in prepaid expenses |
| |
|
| |
Decrease in accounts payable and other current liabilities |
| ( |
|
| ( |
Change in current income taxes |
| |
|
| |
Net change in lease assets and liabilities |
| |
|
| ( |
Increase in other assets |
| ( |
|
| ( |
Increase in other liabilities |
| |
|
| |
Other sources |
| |
|
| |
Net cash provided by operating activities |
| |
|
| |
Cash Flows from Investing Activities |
|
|
|
|
|
Capital expenditures |
| ( |
|
| ( |
Business combinations, net of cash acquired |
| ( |
|
| - |
Proceeds from sale of fixed assets |
| |
|
| |
Other uses |
| ( |
|
| ( |
Net cash used by investing activities |
| ( |
|
| ( |
Cash Flows from Financing Activities |
|
|
|
|
|
Purchases of treasury stock |
| ( |
|
| - |
Proceeds from exercise of stock options |
| |
|
| |
Dividends paid |
| ( |
|
| ( |
Capital stock surrendered to pay taxes on stock-based compensation |
| ( |
|
| ( |
Change in cash overdrafts payable |
| ( |
|
| - |
Payments on other long-term debt |
| - |
|
| ( |
Other uses |
| ( |
|
| ( |
Net cash used by financing activities |
| ( |
|
| ( |
Increase/(Decrease) in Cash and Cash Equivalents |
| |
|
| ( |
Cash and cash equivalents at beginning of period |
| |
|
| |
Cash and cash equivalents at end of period | $ | |
| $ | |
|
|
|
|
|
|
See Accompanying Notes to Unaudited Consolidated Financial Statements. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||
UNAUDITED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY | |||||||||||||||||
(in thousands, except per share data) | |||||||||||||||||
| |||||||||||||||||
For the three months ended March 31, 2024 and 2023: |
|
|
| Deferred |
|
|
| ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Treasury |
|
| Payable in |
|
|
|
|
| Capital |
|
| Paid-in |
|
| Retained |
|
| Stock- |
|
| Company |
|
|
|
|
| Stock |
|
| Capital |
|
| Earnings |
|
| at Cost |
|
| Stock |
|
| Total |
Balance at December 31, 2023 | $ | |
| $ | |
| $ | |
| $ | ( |
| $ | |
| $ | |
Net income |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
Dividends paid ($ |
|
|
|
|
|
|
| ( |
|
|
|
|
|
|
|
| ( |
Stock awards and exercise of stock options |
| |
|
| |
|
|
|
|
| ( |
|
|
|
|
| |
Purchases of treasury stock |
|
|
|
|
|
|
|
|
|
| ( |
|
|
|
|
| ( |
Other |
|
|
|
| ( |
|
|
|
|
| ( |
|
| |
|
| ( |
Balance at March 31, 2024 | $ | |
| $ | |
| $ | |
| $ | ( |
| $ | |
| $ | |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Treasury |
|
| Payable in |
|
|
|
|
| Capital |
|
| Paid-in |
|
| Retained |
|
| Stock- |
|
| Company |
|
|
|
|
| Stock |
|
| Capital |
|
| Earnings |
|
| at Cost |
|
| Stock |
|
| Total |
Balance at December 31, 2022 | $ | |
| $ | |
| $ | |
| $ | ( |
| $ | |
| $ | |
Net income |
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
Dividends paid ($ |
|
|
|
|
|
|
| ( |
|
|
|
|
|
|
|
| ( |
Stock awards and exercise of stock options |
| |
|
| |
|
|
|
|
| ( |
|
|
|
|
| |
Other |
|
|
|
| ( |
|
|
|
|
| ( |
|
| |
|
| ( |
Balance at March 31, 2023 | $ | |
| $ | |
| $ | |
| $ | ( |
| $ | |
| $ | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See Accompanying Notes to Unaudited Consolidated Financial Statements. |
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
Notes to Unaudited Consolidated Financial Statements
We have prepared the accompanying unaudited consolidated financial statements of Chemed in accordance with Rule 10-01 of SEC Regulation S-X. Consequently, we have omitted certain disclosures required under generally accepted accounting principles in the United States (“GAAP”) for complete financial statements. The December 31, 2023 balance sheet data were derived from audited financial statements but do not include all disclosures required by GAAP. However, in our opinion, the financial statements presented herein contain all adjustments, consisting only of normal recurring adjustments, necessary to state fairly our financial position, results of operations and cash flows. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024 or any other future period, and we make no representations related thereto. These financial statements are prepared on the same basis as and should be read in conjunction with the audited Consolidated Financial Statements and related Notes included in our Annual Report on Form 10-K for the year ended December 31, 2023.
As of March 31, 2024, Roto-Rooter has no significant capitalized implementation costs related to cloud computing.
VITAS utilizes a human resources system that is considered a cloud computing arrangement. We have capitalized approximately $
Our effective income tax rate was
Included in the accompanying Consolidated Balance Sheets are $
We account for acquired businesses using the acquisition method of accounting. All assets acquired and liabilities assumed are recorded at their respective fair values at the date of acquisition. The determination of fair value involves estimates and the use of valuation techniques when market value is not readily available. We use various techniques to determine fair value in accordance with accepted valuation models, primarily the income approach. The significant assumptions used in developing fair values include, but are not limited to, revenue growth rates, the amount and timing of future cash flows, discount rates, useful lives, royalty rates and future tax rates. The excess of purchase price over the fair value of assets and liabilities acquired is recorded as goodwill. See Note 17 for discussion of recent acquisitions.
In May 2014, the FASB issued Accounting Standards Update “ASU No. 2014-09 – Revenue from Contracts with Customers.” The standard and subsequent amendments are intended to develop a common revenue standard for removing inconsistencies and
weaknesses, improve comparability, provide for more useful information to users through improved disclosure requirements and simplify the preparation of financial statements. The standard is also referred to as Accounting Standards Codification No. 606 (“ASC 606”).
VITAS
Service revenue for VITAS is reported at the amount that reflects the ultimate consideration we expect to receive in exchange for providing patient care. These amounts are due from third-party payors, primarily commercial health insurers and government programs (Medicare and Medicaid), and include variable consideration for revenue adjustments due to settlements of audits and reviews, as well as certain hospice-specific revenue capitations. Amounts are generally billed monthly or subsequent to patient discharge. Subsequent changes in the transaction price initially recognized are not significant.
Hospice services are provided on a daily basis and the type of service provided is determined based on a physician’s determination of each patient’s specific needs on that given day. Reimbursement rates for hospice services are on a per diem basis regardless of the type of service provided or the payor. Reimbursement rates from government programs are established by the appropriate governmental agency and are standard across all hospice providers. Reimbursement rates from health insurers are negotiated with each payor and generally structured to closely mirror the Medicare reimbursement model. The types of hospice services provided and associated reimbursement model for each are as follows:
Routine Home Care occurs when a patient receives hospice care in their home, including a nursing home setting. The routine home care rate is paid for each day that a patient is in a hospice program and is not receiving one of the other categories of hospice care. For Medicare patients, the routine home care rate reflects a two-tiered rate, with a higher rate for the first
General Inpatient Care occurs when a patient requires services in a controlled setting for a short period of time for pain control or symptom management which cannot be managed in other settings. General inpatient care services must be provided in a Medicare or Medicaid certified hospital or long-term care facility or at a freestanding inpatient hospice facility with the required registered nurse staffing.
Continuous Home Care is provided to patients while at home, including a nursing home setting, during periods of crisis when intensive monitoring and care, primarily nursing care, is required in order to achieve palliation or management of acute medical symptoms. Continuous home care requires a minimum of
Respite Care permits a hospice patient to receive services on an inpatient basis for a short period of time in order to provide relief for the patient’s family or other caregivers from the demands of caring for the patient. A hospice can receive payment for respite care for a given patient for up to five consecutive days at a time, after which respite care is reimbursed at the routine home care rate.
Each level of care represents a separate promise under the contract of care and is provided independently for each patient contingent upon the patient’s specific medical needs as determined by a physician. However, the clinical criteria used to determine a patient’s level of care is consistent across all patients, given that, each patient is subject to the same payor rules and regulations. As a result, we have concluded that each level of care is capable of being distinct and is distinct in the context of the contract. Furthermore, we have determined that each level of care represents a stand ready service provided as a series of either days or hours of patient care. We believe that the performance obligations for each level of care meet criteria to be satisfied over time. VITAS recognizes revenue based on the service output. VITAS believes this to be the most faithful depiction of the transfer of control of services as the patient simultaneously receives and consumes the benefits provided by our performance. Revenue is recognized on a daily or hourly basis for each patient in accordance with the reimbursement model for each type of service. VITAS’ performance obligations relate to contracts with an expected duration of less than one year. Therefore, VITAS has elected to apply the optional exception provided in ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially satisfied performance obligations referred to above relate to bereavement services provided to patients’ families for at least
Care is provided to patients regardless of their ability to pay. Patients who meet our criteria for charity care are provided care without charge. There is
respectively. The cost of charity care is included in cost of services provided and goods sold and is calculated by taking the ratio of charity care days to total days of care and multiplying by the total cost of care.
Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance which vary in amount. VITAS also provides service to patients without a reimbursement source and may offer those patients discounts from standard charges. VITAS estimates the transaction price for patients with deductibles and coinsurance, along with those uninsured patients, based on historical experience and current conditions. The estimate of any contractual adjustments, discounts or implicit price concessions reduces the amount of revenue initially recognized. Subsequent changes to the estimate of the transaction price are recorded as adjustments to patient service revenue in the period of change. Subsequent changes that are determined to be the result of an adverse change in the patients’ ability to pay (i.e. change in credit risk) are recorded as bad debt expense. VITAS has no material adjustments related to subsequent changes in the estimate of the transaction price or subsequent changes as the result of an adverse change in the patient’s ability to pay for any period reported.
Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation and change over time. Medicare and Medicaid programs have broad authority to audit and review compliance with such laws and regulations and impose payment suspensions or modifications when merited. Additionally, the contracts we have with commercial health insurance payors provide for retroactive audit and review of claims. Settlement with third party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. The variable consideration is estimated based on the terms of the payment agreement, existing correspondence from the payor and our historical settlement activity. These estimates are adjusted in future periods, as new information becomes available.
We are subject to certain limitations on Medicare payments for services which are considered variable consideration, as follows:
Inpatient Cap. If the number of inpatient care days any hospice program provides to Medicare beneficiaries exceeds
Medicare Cap. We are also subject to a Medicare annual per-beneficiary cap (“Medicare cap”). Compliance with the Medicare cap is measured in one of two ways based on a provider election. The “streamlined” method compares total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by that Medicare provider number with the product of the per-beneficiary cap amount and the number of Medicare beneficiaries electing hospice care for the first time from that hospice program or programs from September 28 through September 27 of the following year. At March 31, 2024, all our programs except one are using the “streamlined” method.
The “proportional” method compares the total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by the Medicare provider number between September 28 and September 27 of the following year with the product of the per beneficiary cap amount and a pro-rated number of Medicare beneficiaries receiving hospice services from that program during the same period. The pro-rated number of Medicare beneficiaries is calculated based on the ratio of days the beneficiary received hospice services during the measurement period to the total number of days the beneficiary received hospice services.
We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether revenues are likely to exceed the annual per-beneficiary Medicare cap. Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective actions, which include changes to the patient mix and increased patient admissions. However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate revenue recognized during the government fiscal year that will require repayment to the Federal government under the Medicare cap and record an adjustment to revenue of an amount equal to a ratable portion of our best estimate for the year.
For VITAS’ patients in the nursing home setting in which Medicaid pays the nursing home room and board, VITAS serves as a pass-through between Medicaid and the nursing home. We are responsible for paying the nursing home for that patient’s room and board. Medicaid reimburses us for
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Medicare |
| Medicaid |
| Commercial |
| Total | ||||
Routine home care | $ | |
| $ | |
| $ | |
| $ | |
Inpatient care |
| |
|
| |
|
| |
|
| |
Continuous care |
| |
|
| |
|
| |
|
| |
| $ | |
| $ | |
| $ | |
| $ | |
|
|
|
|
|
|
|
|
|
|
|
|
All other revenue - self-pay, respite care, etc. |
|
|
|
|
|
|
|
|
|
| |
Subtotal |
|
|
|
|
|
|
|
|
| $ | |
Medicare cap adjustment |
|
|
|
|
|
|
|
|
|
| ( |
Implicit price concessions |
|
|
|
|
|
|
|
|
|
| ( |
Room and board, net |
|
|
|
|
|
|
|
|
|
| ( |
Net revenue |
|
|
|
|
|
|
|
|
| $ | |
The composition of patient care service revenue by payor and level of care for the quarter ended March 31, 2023 is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
| Medicare |
| Medicaid |
| Commercial |
| Total | ||||
Routine home care | $ | |
| $ | |
| $ | |
| $ | |
Inpatient care |
| |
|
| |
|
| |
|
| |
Continuous care |
| |
|
| |
|
| |
|
| |
| $ | |
| $ | |
| $ | |
| $ | |
|
|
|
|
|
|
|
|
|
|
|
|
All other revenue - self-pay, respite care, etc. |
|
|
|
|
|
|
|
|
|
| |
Subtotal |
|
|
|
|
|
|
|
|
| $ | |
Medicare cap adjustment |
|
|
|
|
|
|
|
|
|
| ( |
Implicit price concessions |
|
|
|
|
|
|
|
|
|
| ( |
Room and board, net |
|
|
|
|
|
|
|
|
|
| ( |
Net revenue |
|
|
|
|
|
|
|
|
| $ | |
Roto-Rooter
Roto-Rooter provides plumbing, drain cleaning, excavation, water restoration and other related services to both residential and commercial customers primarily in the United States. Services are provided through a network of company-owned branches, independent contractors and franchisees. Service revenue for Roto-Rooter is reported at the amount that reflects the ultimate consideration we expect to receive in exchange for providing services.
Roto-Rooter owns and operates branches focusing mainly on large population centers in the United States. Roto-Rooter’s primary lines of business in company-owned branches consist of plumbing, sewer and drain cleaning, excavation and water restoration. For purposes of ASC 606 analysis, plumbing, sewer and drain cleaning, and excavation have been combined into one portfolio and are referred to as “short-term core services”. Water restoration is analyzed as a separate portfolio. The following describes the key characteristics of these portfolios:
Short-term Core Services are plumbing, drain and sewer cleaning and excavation services. These services are provided to both commercial and residential customers. The duration of services provided in this category range from a few hours to a few days. There are no significant warranty costs or on-going obligations to the customer once a service has been completed. For residential customers, payment is received at the time of job completion before the Roto-Rooter technician leaves the residence. Commercial customers may be granted credit subject to internally designated authority limits and credit check guidelines. If credit is granted, payment terms are generally
Each job in this category is a distinct service with a distinct performance obligation to the customer. Revenue is recognized at the completion of each job. Variable consideration consists of pre-invoice discounts and post-invoice discounts. Pre-invoice discounts are given in the form of coupons or price concessions. Post-invoice discounts consist of credit memos generally granted to resolve customer service issues. Variable consideration is estimated based on historical activity and recorded at the time service is completed.
Water Restoration Services involve the remediation of water and humidity after a flood. These services are provided to both commercial and residential customers. The duration of services provided in this category generally ranges from
For both short-term core services and water restoration services, Roto-Rooter satisfies its performance obligation at a point in time. The services provided generally involve fixing plumbing, drainage or flood-related issues at the customer’s property. At the time service is complete, the customer acknowledges its obligation to pay for service and its satisfaction with the service performed. This provides evidence that the customer has accepted the service and Roto-Rooter is now entitled to payment. As such, Roto-Rooter recognizes revenue for these services upon completion of the job and receipt of customer acknowledgement. Roto-Rooter’s performance obligations for short-term core services and water restoration services relate to contracts with an expected duration of less than a year. Therefore, Roto-Rooter has elected to apply the optional exception provided in ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Roto-Rooter does not have significant unsatisfied or partially unsatisfied performance obligations at the time of initial revenue recognition for short-term core or water restoration services.
Roto-Rooter owns the rights to certain territories and contracts with independent third-parties to operate the territory under Roto-Rooter’s registered trademarks (“independent contractors”). Such contracts are for a specified term but cancellable by either party without penalty with
Independent contractors pay Roto-Rooter a standard fee calculated as a percentage of their cash collection from weekly sales. The primary value for the independent contractors under these arrangements is the right to use Roto-Rooter’s registered trademarks. Roto-Rooter recognizes revenue from independent contractors over-time (weekly) as the independent contractor’s labor sales are completed and payment from customers are received. Payment from independent contractors is also received on a weekly basis. The use of Roto-Rooter’s registered trademarks and advertising provides immediate value to the independent contractor as a result of Roto-Rooter’s nationally recognized brand. Therefore, over-time recognition provides the most faithful depiction of the transfer of services as the customer simultaneously receives and consumes the benefits provided. There is no significant variable consideration related to these arrangements.
Roto-Rooter has licensed the rights to operate under Roto-Rooter’s registered trademarks in other territories to franchisees. Each such contract is for a
Roto-Rooter’s registered trademarks. The franchisee is responsible for all day-to-day management of the business including staffing decisions, pricing of services provided and local advertising spend and placement. All performance obligations of Roto-Rooter cease at the termination of the arrangement.
Franchisees pay Roto-Rooter a standard monthly fee based on the population within the franchise territory. The standard fee is revised on a yearly basis based on changes in the Consumer Price Index for All Urban Consumers. The primary value for the franchisees under this arrangement is the right to use Roto-Rooter’s registered trademarks. Roto-Rooter recognizes revenue from franchisees over-time (monthly). Payment from franchisees is also received on a monthly basis. The use of Roto-Rooter’s registered trademarks and advertising provides immediate value to the franchisees as a result of Roto-Rooter’s nationally recognized brand. Therefore, over-time recognition provides the most faithful depiction of the transfer of services as the customer simultaneously receives and consumes the benefits provided. There is no significant variable consideration related to these arrangements.
|
|
|
|
|
|
| March 31, | ||||
| 2024 |
| 2023 | ||
Drain cleaning | $ | |
| $ | |
Plumbing |
| |
|
| |
Excavation |
| |
|
| |
Other |
| |
|
| |
Subtotal - short term core |
| |
|
| |
Water restoration |
| |
|
| |
Independent contractors |
| |
|
| |
Franchisee fees |
| |
|
| |
Other |
| |
|
| |
Gross revenue |
| |
|
| |
Implicit price concessions and credit memos |
| ( |
|
| ( |
Net revenue | $ | |
| $ | |
|
|
|
|
|
|
3. Segments
Service revenues and sales by business segment are shown in Note 2. After-tax income/(loss) by business segment are as follows (in thousands):
|
|
|
|
|
|
|
| ||||
| Three months ended March 31, | ||||
| 2024 |
| 2023 | ||
VITAS | $ | |
| $ | |
Roto-Rooter |
| |
|
| |
Total |
| |
|
| |
Corporate |
| ( |
|
| ( |
Net income | $ | |
| $ | |
We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”.
Earnings per share (“EPS”) are computed using the weighted average number of shares of capital stock outstanding. Earnings and diluted earnings per share are computed as follows (in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net Income | |||||
For the Three Months Ended March 31, |
| Income |
| Shares |
| Earnings per Share | |||
2024 |
|
|
|
|
|
|
|
|
|
| Earnings |
| $ | |
| |
| $ | |
| Dilutive stock options |
|
| - |
| |
|
|
|
| Nonvested stock awards |
|
| - |
| |
|
|
|
| Diluted earnings |
| $ | |
| |
| $ | |
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
| Earnings |
| $ | |
| |
| $ | |
| Dilutive stock options |
|
| - |
| |
|
|
|
| Nonvested stock awards |
|
| - |
| |
|
|
|
| Diluted earnings |
| $ | |
| |
| $ | |
|
|
|
|
|
|
|
|
|
|
For the three months ended March 31, 2024, there were
On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a $
We made prepayments totaling $
The 2022 Credit Facilities contain the following quarterly financial covenants effective as of March 31, 2024:
|
|
|
|
|
|
Description |
| Requirement |
|
|
|
Leverage Ratio (Consolidated Indebtedness/Consolidated Adj. EBITDA) |
| < |
|
|
|
Interest Coverage Ratio (Consolidated Adj. EBITDA/Consolidated Interest Expense) |
| > |
|
|
|
We are in compliance with all debt covenants as of March 31, 2024. We have issued $
Other income/(expense) – net comprises the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
| Three months ended March 31, | ||||
| 2024 |
| 2023 | ||
Market value adjustment on assets held in |
|
|
|
| |
deferred compensation trust | $ | |
| $ | ( |
Interest income |
| |
|
| |
Other-net |
| - |
|
| |
Total other income/(expense) - net | $ | |
| $ | ( |
Chemed and each of its operating subsidiaries are service companies. As such, real estate leases comprise the largest lease obligation (and conversely, right of use asset) in our lease portfolio. VITAS has leased office space, as well as space for inpatient units (“IPUs”) and/or contract beds within hospitals. Roto-Rooter mainly has leased office space. Our leases have remaining terms of under
Roto-Rooter purchases equipment and leases it to certain of its independent contractors. We analyzed these leases in accordance with ASC 842 and determined they are operating leases. As a result, Roto-Rooter capitalizes the equipment underlying these leases, depreciates the equipment and recognizes rental income.
We do
The components of balance sheet information related to leases were as follows:
|
|
|
|
|
|
| March 31, |
|
| ||
| 2024 |
| 2023 | ||
Assets |
|
|
|
|
|
Operating lease assets | $ | |
| $ | |
|
|
|
|
|
|
Liabilities |
|
|
|
|
|
Current operating leases |
| |
|
| |
Noncurrent operating leases |
| |
|
| |
Total operating lease liabilities | $ | |
| $ | |
The components of lease expense for the first quarter are as follows (in thousands):
|
|
|
|
|
|
| Three months ended March 31, | ||||
| 2024 |
| 2023 | ||
Lease Expense (a) |
|
|
|
|
|
Operating lease expense | $ | |
| $ | |
Sublease income |
| ( |
|
| ( |
Net lease expense | $ | |
| $ | |
(a)
The components of cash flow information related to leases were as follows:
|
|
|
|
|
|
| Three months ended March 31, | ||||
| 2024 |
| 2023 | ||
Cash paid for amounts included in the measurement of lease liabilities |
|
|
|
|
|
Operating cash flows from leases | $ | |
| $ | |
|
|
|
|
|
|
Leased assets obtained in exchange for new operating lease liabilities | $ | |
| $ | |
|
|
|
|
|
|
|
|
|
|
Weighted Average Remaining Lease Term at March 31, 2024 |
|
|
|
Operating leases |
| years |
|
|
|
|
Weighted Average Discount Rate at March 31, 2024 |
|
|
|
Operating leases |
| % |
|
|
|
|
|
|
Maturity of Operating Lease Liabilities (in thousands) |
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
|
| $ | |
2025 |
|
|
|
| |
2026 |
|
|
|
| |
2027 |
|
|
|
| |
2028 |
|
|
|
| |
Thereafter |
|
|
|
| |
Total lease payments |
|
|
| $ | |
Less: interest |
|
|
|
| ( |
Total liability recognized on the balance sheet |
|
|
| $ | |
On February 16, 2024, the Compensation/Incentive Committee of the Board of Directors (“CIC”) granted
On February 16, 2024, the CIC also granted
At the end of 2023, the then Chief Financial Officer (CFO) transitioned to an employee advisor role. In early 2024, in connection with this change of roles, the CFO’s employment agreement terminated, and the CFO was given a one-time grant of
All of the Company’s plans that provide retirement and similar benefits are defined contribution plans. These expenses include the impact of market gains and losses on assets held in deferred compensation plans and are recorded in selling, general and administrative expenses. Net gains for the Company’s retirement and profit-sharing plans, excess benefit plans and other similar plans are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, | ||||
2024 |
| 2023 | ||
$ | |
| $ | |
The VITAS segment of the Company’s business operates in a heavily-regulated industry. As a result, the Company is subjected to inquiries and investigations by various government agencies, which can result in penalties including repayment obligations, funding withholding, or debarment, as well as to lawsuits, including qui tam actions. The following sections describe the various ongoing material lawsuits and investigations of which the Company is currently aware. Other than as described below, it is not possible at this time for us to estimate either the timing or outcome of any of those matters, or whether any potential loss, or range of potential losses, is probable or reasonably estimable.
Regulatory Matters and Litigation
VITAS is one of a group of hospice providers selected by the Office of the Inspector General’s (“OIG”) Office of Audit Services (“OAS”) for inclusion in an audit of the provision of elevated level-of-care hospice services. On July 14, 2022, VITAS received the final audit report from OAS. Per this report, the OAS audit examined VITAS inpatient and continuous care claims for the period April 2017 to March 2019. The audit covered a total population of
On August 29, 2022, six weeks subsequent to the OAS finalizing its audit, VITAS received a demand letter from its Medicare Administrative Contractor (“MAC”) seeking repayment of $
Regardless of the outcome of any of the preceding matters, dealing with the various regulatory agencies and opposing parties can adversely affect us through defense costs, potential payments, withholding of governmental funding, diversion of management time, and related publicity. Although the Company intends to defend them vigorously, there can be no assurance that those suits will not have a material adverse effect on the Company.
As of March 31, 2024, and December 31, 2023, approximately
VITAS has a pharmacy services contract with
There is $
13. Other Assets
Other assets comprise the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
| March 31, |
| December 31, | ||
| 2024 |
| 2023 | ||
|
|
|
|
|
|
Deposit with OAS | $ | |
| $ | |
Cash surrender value life insurance |
| |
|
| |
Noncurrent advances and deposits |
| |
|
| |
Deferred debt costs |
| |
|
| |
Other |
| |
|
| |
Total other assets | $ | |
| $ | |
14. Other Current Liabilities
|
|
|
|
|
|
| March 31, |
| December 31, | ||
| 2024 |
| 2023 | ||
|
|
|
|
|
|
Medicare Cap | $ | |
| $ | |
Healthcare worker retention bonus |
| |
|
| |
Accrued advertising |
| |
|
| |
All other |
| |
|
| |
Total other current liabilities | $ | |
| $ | |
FASB’s authoritative guidance on fair value measurements defines a hierarchy which prioritizes the inputs in fair value measurements. Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities. Level 2 measurements use significant other observable inputs. Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions. In recording the fair value of assets and liabilities, companies must use the most reliable measurement available.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value Measure | ||||||
|
|
| Carrying Value |
|
| Quoted Prices in Active Markets for Identical Assets (Level 1) |
|
| Significant Other Observable Inputs (Level 2) |
|
| Significant Unobservable Inputs (Level 3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments of deferred compensation plans held in trust |
| $ | |
| $ | |
| $ | - |
| $ | - |
Cash equivalents |
|
| |
|
| |
|
| - |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
The following shows the carrying value, fair value and the hierarchy for our financial instruments as of December 31, 2023 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value Measure | ||||||
|
|
| Carrying Value |
|
| Quoted Prices in Active Markets for Identical Assets (Level 1) |
|
| Significant Other Observable Inputs (Level 2) |
|
| Significant Unobservable Inputs (Level 3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments of deferred compensation plans held in trust |
| $ | |
| $ | |
| $ | - |
| $ | - |
Cash equivalents |
|
| |
|
| |
|
| - |
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
We repurchased the following capital stock:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Three months ended March 31, |
| ||||
|
| 2024 |
| 2023 |
| ||
|
|
|
|
|
|
|
|
Total cost of repurchased shares (in thousands) |
| $ | |
| $ | - |
|
Shares repurchased |
|
| |
|
| - |
|
Weighted average price per share |
| $ | |
| $ | - |
|
17. Acquisitions
On March 11, 2024, Roto-Rooter completed the acquisition of
Goodwill is assessed for impairment on a yearly basis as of October 1. All goodwill recognized is deductible for tax purposes.
Shown below is movement in Goodwill (in thousands):
|
|
|
|
|
|
|
|
|
| VITAS |
| Roto-Rooter |
| Total | |||
Balance at December 31, 2023 | $ | |
| $ | |
| $ | |
Business combinations |
| - |
|
| |
|
| |
Foreign currency adjustments |
| - |
|
| ( |
|
| ( |
Balance at March 31, 2024 | $ | |
| $ | |
| $ | |
18. Recent Accounting Standards
In November 2023, the FASB issued Accounting Standards Update “ASU 2023-07 – Reportable Segments”. The guidance provides enhanced disclosures about significant segment expenses. The purpose of the amendment is to provide investors with a better understanding of an entity’s overall performance and assess potential future cash flows. The guidance is effective for fiscal periods beginning after December 31, 2023, and interim periods within fiscal years beginning after December 31, 2024. The Company is currently analyzing the impact of the ASU on the current footnote disclosures.
In December 2023, the FASB issued Accounting Standards Update “ASU 2023-09 – Income Tax Disclosure”. The guidance provides increased transparency related to tax risk and tax planning through (1) disclosure in specific categories in the rate reconciliation and (2) provide additional information for reconciling items when a quantitative threshold is met. The guidance is effective for fiscal periods beginning after December 31, 2024. The Company is currently analyzing the impact of the ASU on the current footnote disclosures.
VITAS completed the previously announced purchase of all hospice operations and an assisted living facility from Covenant Health and Community Services, Inc d/b/a/ Covenant Care (“Covenant”) for an aggregated purchase price of $
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Executive Summary
We operate through our two wholly-owned subsidiaries, VITAS Healthcare Corporation and Roto-Rooter Group, Inc. VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its teams of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter’s services are focused on providing plumbing, drain cleaning, excavation, water restoration and other related services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.
The vast majority of the Company’s operations are located in the United States. As both operations are service companies, our employees are the most critical resource of the Company. We have very little exposure related to customers, vendors, or employees in other regions of the world.
The following is a summary of the key operating results (in thousands except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Three months ended March 31, |
| ||||
| 2024 |
| 2023 |
| ||
Service revenues and sales | $ | 589,233 |
| $ | 560,157 |
|
Net income | $ | 65,017 |
| $ | 54,121 |
|
Diluted EPS | $ | 4.24 |
| $ | 3.58 |
|
Adjusted net income | $ | 79,831 |
| $ | 64,723 |
|
Adjusted diluted EPS | $ | 5.20 |
| $ | 4.28 |
|
Adjusted EBITDA | $ | 114,622 |
| $ | 100,117 |
|
Adjusted EBITDA as a % of revenue |
| 19.5 | % |
| 17.9 | % |
Adjusted net income, adjusted diluted EPS, earnings before interest, taxes and depreciation and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA as a percent of revenue are not measures derived in accordance with US GAAP. We provide non-GAAP measures to help readers evaluate our operating results and to compare our operating performance with that of similar companies that have different capital structures. Our non-GAAP measures should not be considered in isolation or as a substitute for comparable measures presented in accordance with GAAP. A reconciliation of our non-GAAP measures is presented on pages 27-28.
For the three months ended March 31, 2024, the increase in consolidated service revenues and sales was driven by a 14.0% increase at VITAS offset by a 5.8% decrease at Roto-Rooter. The increase in service revenues at VITAS is comprised primarily of a 11.5% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth 60-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 50-basis points. The decrease in service revenues at Roto-Rooter was driven by a decrease in all service lines.
The pandemic resulted in a significant shortage of licensed healthcare workers industry wide. VITAS has not been immune to this shortage. As a result, on July 1, 2022, VITAS implemented a hiring and retention bonus program for its licensed healthcare workers. It was a temporary program that helped VITAS attract and retain licensed healthcare workers during the pandemic- induced healthcare worker shortage. An eligible employee must continue in employment for a period of one-year from July 1, 2022 to receive a bonus. Additionally, employees hired between July 1, 2022 and June 30, 2023 were eligible if they continue employment for a one-year period from their hire date. A total of $39.7 million has been accrued since the start of the program. Payments totaling $33.6 million have been made from July 2023 to March 2024. The remaining accrued amount will be paid over the next two quarters. For the quarter ended March 31, 2023, the pre-tax cost of the retention program was $10.9 million. There was no material impact on the financial results for the quarter ended March 31, 2024. See page 29 for additional VITAS operating metrics.
Starting September 30, 2023, Chemed no longer excluded the cost of the Retention Program when presenting non-GAAP operating metrics in current or prior periods.
On June 28, 2022, we replaced our existing credit facility with a fifth amended and restated Credit Agreement (“2022 Credit Facilities”). Terms of the 2022 Credit Facilities consist of a five-year $450.0 million revolver as well as a five-year $100.0 million term loan. Principal payments of $1.25 million on the term loan are due on the last day of each fiscal quarter, with a final payment due at the end of the agreement. The 2022 Credit Facilities have a floating interest rate that is generally SOFR plus an additional tiered rate which varies based on our current leverage ratio. As of March 31, 2024, the interest rate is SOFR plus 100 basis points. The 2022 Credit
Facilities include an expansion feature that provides the Company the opportunity to increase its revolver and/or term loan by an additional $250.0 million.
We made prepayments totaling $75.0 million in the first quarter of 2023, on the $100.0 million term loan. We paid the remaining balance of $21.3 million on April 28, 2023. There were no prepayment penalties associated with this repayment. This prepayment reduced the total borrowing capacity of the 2022 Credit Facilities from $550.0 million to $450.0 million.
We have issued $45.2 million in standby letters of credit as of March 31, 2024, mainly for insurance purposes. Issued letters of credit reduce our available credit under the 2022 Credit Facilities. As of March 31, 2024, we have approximately $404.8 million of unused lines of credit available and are eligible to be drawn down under our revolving credit facility. Management believes its liquidity and sources of capital are satisfactory for the Company’s needs in the foreseeable future.
We anticipate that our operating income and cash flows will be sufficient to operate our business and meet any commitments for the foreseeable future.
Financial Condition
Liquidity and Capital Resources
Material changes in the balance sheet accounts from December 31, 2023 to March 31, 2024 include the following:
A $11.5 million increase in investments of deferred compensation plans due mainly to market valuation gains. This resulted in a similar increase in the liability associated with deferred compensation plans.
A $5.4 million increase in lease right of use asset due to lease renewals. This resulted in a similar increase in the long-term lease liability.
A $6.5 million increase in goodwill due to acquisitions at Roto-Rooter.
A $20.5 million increase in income taxes due to timing of payments.
A $38.6 million decline in accrued compensation due primarily to the payment of 2023 bonuses in the first quarter of 2024.
A $9.1 million decrease in other current liabilities due to payments of the retention bonus program implemented at VITAS and a decrease in the Medicare Cap liability at VITAS.
Net cash provided by operating activities increased $24.1 million from March 31, 2023 to March 31, 2024. The main drivers are an increase in earnings of $10.9 million and an increase of $7.1 million in noncash long-term incentive compensation. Significant changes in our accounts receivable balances are typically driven by the timing of payments received from the Federal government at our VITAS subsidiary. We typically receive a payment in excess of $51.0 million from the Federal government for hospice services every other Friday. The timing of a period end will have a significant impact on the accounts receivable at VITAS. These changes generally normalize over a two-year period, as cash flow variations in one year are offset in the following year.
Management continually evaluates cash utilization alternatives, including share repurchase, debt repurchase, acquisitions and increased dividends to determine the most beneficial use of available capital resources.
Commitments and Contingencies
Collectively, the terms of the 2022 Credit Facilities require us to meet various financial covenants, to be tested quarterly. We are in compliance with all financial and other debt covenants as of March 31, 2024 and anticipate remaining in compliance throughout the foreseeable future.
We are subject to various lawsuits and claims in the normal course of our business. In addition, we periodically receive communications from governmental and regulatory agencies concerning compliance with Medicare and Medicaid billing requirements at our VITAS subsidiary. We establish reserves for specific, uninsured liabilities in connection with regulatory and legal action that we deem to be probable and estimable. We disclose the existence of regulatory and legal actions when we believe it is reasonably possible that a loss could occur in connection with the specific action. In most instances, we are unable to make a reasonable estimate of any reasonably possible liability due to the uncertainty of the outcome and stage of litigation. We record legal fees associated with legal and regulatory actions as the costs are incurred.
See Note 10 in the Notes to the Unaudited Consolidated Financial Statements in Item 1 above for a description of current material legal matters.
Results of Operations
Three months ended March 31, 2024 versus 2023 - Consolidated Results
Our service revenues and sales for the first quarter of 2024 increased 5.2% versus services and sales revenues for the first quarter of 2023. Of this increase, a $43.5 million increase was attributable to VITAS, offset by a $14.5 million decrease at Roto-Rooter. The following chart shows the components of revenue by operating segment (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Three months ended March 31, |
| Increase/(Decrease) | ||||
|
| 2024 |
| 2023 |
| Percent | ||
VITAS |
|
|
|
|
|
|
|
|
Routine homecare |
| $ | 304,860 |
| $ | 267,050 |
| 14.2 |
General inpatient |
|
| 30,303 |
|
| 29,093 |
| 4.2 |
Continuous care |
|
| 24,169 |
|
| 19,941 |
| 21.2 |
Other |
|
| 4,084 |
|
| 3,021 |
| 35.2 |
Subtotal |
|
| 363,416 |
|
| 319,105 |
| 13.9 |
Medicare cap adjustment |
|
| (2,375) |
|
| (2,750) |
| 13.6 |
Room and board - net |
|
| (2,944) |
|
| (2,769) |
| (6.3) |
Implicit price concessions |
|
| (4,090) |
|
| (3,108) |
| (31.6) |
Net revenue |
| $ | 354,007 |
| $ | 310,478 |
| 14.0 |
|
|
|
|
|
|
|
|
|
Roto-Rooter |
|
|
|
|
|
|
|
|
Drain cleaning |
| $ | 61,621 |
| $ | 66,489 |
| (7.3) |
Plumbing |
|
| 48,098 |
|
| 50,453 |
| (4.7) |
Excavation |
|
| 58,618 |
|
| 59,576 |
| (1.6) |
Other |
|
| 244 |
|
| 193 |
| 26.4 |
Subtotal - short term core |
|
| 168,581 |
|
| 176,711 |
| (4.6) |
Water restoration |
|
| 46,678 |
|
| 50,762 |
| (8.0) |
Independent contractors |
|
| 19,616 |
|
| 23,300 |
| (15.8) |
Outside franchisee fees |
|
| 1,491 |
|
| 1,351 |
| 10.4 |
Other |
|
| 6,015 |
|
| 4,745 |
| 26.8 |
Gross revenue |
|
| 242,381 |
|
| 256,869 |
| (5.6) |
Implicit price concessions |
|
| (7,155) |
|
| (7,190) |
| 0.5 |
Net revenue |
|
| 235,226 |
|
| 249,679 |
| (5.8) |
Total Revenues |
| $ | 589,233 |
| $ | 560,157 |
| 5.2 |
Days of care at VITAS during the quarters were as follows:
|
|
|
|
|
|
| Three months ended March 31, |
| Increase/(Decrease) | ||
| 2024 |
| 2023 |
| Percent |
|
|
|
|
|
|
Routine homecare | 1,447,912 |
| 1,286,437 |
| 12.6 |
Nursing home | 283,158 |
| 265,429 |
| 6.7 |
Respite | 7,752 |
| 5,760 |
| 34.6 |
Subtotal routine homecare and respite | 1,738,822 |
| 1,557,626 |
| 11.6 |
General inpatient | 26,645 |
| 26,369 |
| 1.0 |
Continuous care | 24,037 |
| 20,686 |
| 16.2 |
Total days of care | 1,789,504 |
| 1,604,681 |
| 11.5 |
The increase in service revenues at VITAS is comprised primarily of an 11.5% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth by 60-basis points in the quarter when compared to the prior year revenue and level-of-care mix. The combination of Medicare cap and other contra revenue changes increased revenue growth by 50-basis.
The decrease in plumbing revenues for the first quarter of 2024 versus 2023 is attributable to a 2.2% decrease in price and service mix shift and by a 2.5% decrease in job count. The decrease in drain cleaning revenues for the first quarter of 2024 versus 2023
is attributable to a 9.2% decrease in job count offset by a 1.9% increase in price and service mix. Excavation and water restoration jobs are generally sold as a result of initial calls from customers regarding drain cleaning issues.
The consolidated gross margin was 34.6% in the first quarter of 2024 as compared with 33.8% in the first quarter of 2023. On a segment basis, VITAS’ gross margin was 23.2% in the first quarter of 2024 as compared with 18.3%, in the first quarter of 2023. The increase in gross margin at VITAS is mostly the result of increased revenues and the expiration of the licensed healthcare worker retention bonus program in 2023. The Roto-Rooter segment’s gross margin was 51.9% for the first quarter of 2024 as compared with 53.1% in the first quarter of 2023. This decline was mainly the result of declining revenue.
Selling, general and administrative expenses (“SG&A”) comprise (in thousands):
|
|
|
|
|
|
| Three months ended March 31, | ||||
| 2024 |
| 2023 | ||
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts | $ | 98,418 |
| $ | 97,902 |
Long-term incentive compensation |
| 9,121 |
|
| 2,514 |
Impact of market value adjustments related to assets held in deferred compensation trusts |
| 8,334 |
|
| (321) |
Total SG&A expenses | $ | 115,873 |
| $ | 100,095 |
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation trusts for the first quarter of 2024 were up 0.5% when compared to first quarter of 2023.
Other income/(expense) – net comprise (in thousands):
|
|
|
|
|
|
| Three months ended March 31, | ||||
| 2024 |
| 2023 | ||
Market value adjustment on assets held in deferred compensation trusts | $ | 8,334 |
| $ | (321) |
Interest income |
| 4,243 |
|
| 150 |
Other |
| - |
|
| 68 |
Total other income/(expense) - net | $ | 12,577 |
| $ | (103) |
We invest excess cash in money market funds with major commercial banks. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds. In 2023, Chemed began investing excess cash in a money market fund holding US Treasuries. Deposits and withdrawals are made daily, based on the Company’s excess cash balance. There are no penalties associated with withdrawals. The accounts bear interest at a normal market rate.
Our effective tax rate reconciliation is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
| Three months ended March 31, |
| |||||
|
| 2024 |
|
| 2023 |
| ||
|
|
|
|
|
|
|
|
|
Income tax provision calculated at the statutory federal rate |
| $ | 17,742 |
|
| $ | 14,945 |
|
Stock compensation tax benefits |
|
| (3,297) |
|
|
| (1,650) |
|
State and local income taxes |
|
| 2,961 |
|
|
| 2,940 |
|
Other--net |
|
| 2,062 |
|
|
| 809 |
|
Income tax provision |
| $ | 19,468 |
|
| $ | 17,044 |
|
Effective tax rate |
|
| 23.0 | % |
|
| 23.9 | % |
Net income for both periods included the following after-tax items/adjustments that (reduced) or increased after-tax earnings (in thousands):
|
|
|
|
|
|
| Three months ended March 31, | ||||
| 2024 |
| 2023 | ||
Roto-Rooter |
|
|
|
|
|
Amortization of reacquired franchise agreements | $ | (1,804) |
| $ | (1,729) |
Litigation settlements |
| - |
|
| (1,290) |
Corporate |
|
|
|
|
|
Stock option expense |
| (7,555) |
|
| (7,010) |
Severance arrangement |
| (5,337) |
|
| - |
Long-term incentive compensation |
| (3,415) |
|
| (2,223) |
Excess tax benefits on stock compensation |
| 3,297 |
|
| 1,650 |
Total | $ | (14,814) |
| $ | (10,602) |
Three months ended March 31, 2024 versus 2023 - Segment Results
Net income/(loss) for the first quarter of 2024 versus the first quarter of 2023 by segment (in thousands):
|
|
|
|
|
|
|
|
|
| ||
| Three months ended March 31, | ||||
| 2024 |
| 2023 | ||
VITAS | $ | 43,970 |
| $ | 24,764 |
Roto-Rooter |
| 40,853 |
|
| 47,653 |
Corporate |
| (19,806) |
|
| (18,296) |
| $ | 65,017 |
| $ | 54,121 |
After-tax earnings as a percent of revenue at VITAS in the first quarter of 2024 was 12.4% as compared to 8.0% in the first quarter of 2023. VITAS’ after-tax earnings increased primarily due to increased revenues and the expiration of the licensed healthcare worker retention bonus program in 2023.
Roto-Rooter’s net income was negatively impacted in the first quarter of 2024 compared to the first quarter of 2023 primarily due to declining revenue. After-tax earnings as a percent of revenue at Roto-Rooter in the first quarter of 2024 was 17.4%, as compared to 19.1% in the first quarter of 2023.
After-tax Corporate expenses for the first quarter of 2024 increased 8.3% when compared to the first quarter in 2023 due primarily to a $1.7 million increase in stock-based compensation.
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||
CONSOLIDATING STATEMENTS OF INCOME | |||||||||||
FOR THE THREE MONTHS ENDED MARCH 31, 2024 | |||||||||||
(in thousands)(unaudited) | |||||||||||
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| Chemed | ||||
| VITAS |
| Roto-Rooter |
| Corporate |
| Consolidated | ||||
2024 (a) |
|
|
|
|
|
|
|
|
|
|
|
Service revenues and sales | $ | 354,007 |
| $ | 235,226 |
| $ | - |
| $ | 589,233 |
Cost of services provided and goods sold |
| 271,896 |
|
| 113,231 |
|
| - |
|
| 385,127 |
Selling, general and administrative expenses |
| 23,792 |
|
| 61,260 |
|
| 30,821 |
|
| 115,873 |
Depreciation |
| 5,166 |
|
| 8,108 |
|
| 13 |
|
| 13,287 |
Amortization |
| 26 |
|
| 2,495 |
|
| - |
|
| 2,521 |
Other operating expense |
| 7 |
|
| 85 |
|
| - |
|
| 92 |
Total costs and expenses |
| 300,887 |
|
| 185,179 |
|
| 30,834 |
|
| 516,900 |
Income/(loss) from operations |
| 53,120 |
|
| 50,047 |
|
| (30,834) |
|
| 72,333 |
Interest expense |
| (46) |
|
| (117) |
|
| (262) |
|
| (425) |
Intercompany interest income/(expense) |
| 5,194 |
|
| 3,442 |
|
| (8,636) |
|
| - |
Other income—net |
| 29 |
|
| 22 |
|
| 12,526 |
|
| 12,577 |
Income/(expense) before income taxes |
| 58,297 |
|
| 53,394 |
|
| (27,206) |
|
| 84,485 |
Income taxes |
| (14,327) |
|
| (12,541) |
|
| 7,400 |
|
| (19,468) |
Net income/(loss) | $ | 43,970 |
| $ | 40,853 |
| $ | (19,806) |
| $ | 65,017 |
|
|
|
|
|
|
|
|
|
|
|
|
(a) The following amounts are included in net income (in thousands): | |||||||||||
|
|
|
|
|
|
|
|
|
| Chemed | |
| VITAS |
| Roto-Rooter |
| Corporate |
| Consolidated | ||||
Pretax benefit/(cost): |
|
|
|
|
|
|
|
|
|
|
|
Stock option expense | $ | - |
| $ | - |
| $ | (9,026) |
| $ | (9,026) |
Severance arrangement |
| - |
|
| - |
|
| (5,337) |
|
| (5,337) |
Long-term incentive compensation |
| - |
|
| - |
|
| (3,784) |
|
| (3,784) |
Amortization of reacquired franchise agreements |
| - |
|
| (2,352) |
|
| - |
|
| (2,352) |
Total | $ | - |
| $ | (2,352) |
| $ | (18,147) |
| $ | (20,499) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chemed | |
| VITAS |
| Roto-Rooter |
| Corporate |
| Consolidated | ||||
After-tax benefit/(cost): |
|
|
|
|
|
|
|
|
|
|
|
Stock option expense | $ | - |
| $ | - |
| $ | (7,555) |
| $ | (7,555) |
Severance arrangement |
| - |
|
| - |
|
| (5,337) |
|
| (5,337) |
Long-term incentive compensation |
| - |
|
| - |
|
| (3,415) |
|
| (3,415) |
Amortization of reacquired franchise agreements |
| - |
|
| (1,804) |
|
| - |
|
| (1,804) |
Excess tax benefits on stock compensation |
| - |
|
| - |
|
| 3,297 |
|
| 3,297 |
Total | $ | - |
| $ | (1,804) |
| $ | (13,010) |
| $ | (14,814) |
|
|
|
|
|
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||
CONSOLIDATING STATEMENTS OF INCOME | |||||||||||
FOR THE THREE MONTHS ENDED MARCH 31, 2023 | |||||||||||
(in thousands)(unaudited) | |||||||||||
|
|
|
|
|
|
|
|
| |||
|
|
|
|
|
|
| Chemed | ||||
| VITAS |
| Roto-Rooter |
| Corporate |
| Consolidated | ||||
2023 (a) |
|
|
|
|
|
|
|
|
|
|
|
Service revenues and sales | $ | 310,478 |
| $ | 249,679 |
| $ | - |
| $ | 560,157 |
Cost of services provided and goods sold |
| 253,654 |
|
| 117,051 |
|
| - |
|
| 370,705 |
Selling, general and administrative expenses |
| 23,336 |
|
| 60,813 |
|
| 15,946 |
|
| 100,095 |
Depreciation |
| 4,958 |
|
| 7,312 |
|
| 16 |
|
| 12,286 |
Amortization |
| 26 |
|
| 2,487 |
|
| - |
|
| 2,513 |
Other operating expense |
| 12 |
|
| 1,727 |
|
| - |
|
| 1,739 |
Total costs and expenses |
| 281,986 |
|
| 189,390 |
|
| 15,962 |
|
| 487,338 |
Income/(loss) from operations |
| 28,492 |
|
| 60,289 |
|
| (15,962) |
|
| 72,819 |
Interest expense |
| (50) |
|
| (133) |
|
| (1,368) |
|
| (1,551) |
Intercompany interest income/(expense) |
| 4,648 |
|
| 2,743 |
|
| (7,391) |
|
| - |
Other (expense)/income—net |
| 189 |
|
| 29 |
|
| (321) |
|
| (103) |
Income/(expense) before income taxes |
| 33,279 |
|
| 62,928 |
|
| (25,042) |
|
| 71,165 |
Income taxes |
| (8,515) |
|
| (15,275) |
|
| 6,746 |
|
| (17,044) |
Net income/(loss) | $ | 24,764 |
| $ | 47,653 |
| $ | (18,296) |
| $ | 54,121 |
|
|
|
|
|
|
|
|
|
|
|
|
(a) The following amounts are included in net income (in thousands): | |||||||||||
|
|
|
|
|
|
|
|
|
| Chemed | |
| VITAS |
| Roto-Rooter |
| Corporate |
| Consolidated | ||||
Pretax benefit/(cost): |
|
|
|
|
|
|
|
|
|
|
|
Stock option expense | $ | - |
| $ | - |
| $ | (8,482) |
| $ | (8,482) |
Long-term incentive compensation |
| - |
|
| - |
|
| (2,514) |
|
| (2,514) |
Amortization of reacquired franchise agreements |
| - |
|
| (2,352) |
|
| - |
|
| (2,352) |
Litigation settlements |
| - |
|
| (1,756) |
|
| - |
|
| (1,756) |
Total | $ | - |
| $ | (4,108) |
| $ | (10,996) |
| $ | (15,104) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chemed | |
| VITAS |
| Roto-Rooter |
| Corporate |
| Consolidated | ||||
After-tax benefit/(cost): |
|
|
|
|
|
|
|
|
|
|
|
Stock option expense | $ | - |
| $ | - |
| $ | (7,010) |
| $ | (7,010) |
Long-term incentive compensation |
| - |
|
| - |
|
| (2,223) |
|
| (2,223) |
Amortization of reacquired franchise agreements |
| - |
|
| (1,729) |
|
| - |
|
| (1,729) |
Litigation settlements |
| - |
|
| (1,290) |
|
| - |
|
| (1,290) |
Excess tax benefits on stock compensation |
| - |
|
| - |
|
| 1,650 |
|
| 1,650 |
Total | $ | - |
| $ | (3,019) |
| $ | (7,583) |
| $ | (10,602) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unaudited Consolidating Summary and Reconciliation of Adjusted EBITDA | ||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
Chemed Corporation and Subsidiary Companies |
|
|
| |||||||||
(in thousands) |
|
|
|
|
|
|
|
|
| Chemed | ||
For the three months ended March 31, 2024 | VITAS |
| Roto-Rooter |
| Corporate |
| Consolidated | |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income/(loss) | $ | 43,970 |
| $ | 40,853 |
| $ | (19,806) |
| $ | 65,017 |
| Add/(deduct): |
|
|
|
|
|
|
|
|
|
|
|
| Interest expense |
| 46 |
|
| 117 |
|
| 262 |
|
| 425 |
| Income taxes |
| 14,327 |
|
| 12,541 |
|
| (7,400) |
|
| 19,468 |
| Depreciation |
| 5,166 |
|
| 8,108 |
|
| 13 |
|
| 13,287 |
| Amortization |
| 26 |
|
| 2,495 |
|
| - |
|
| 2,521 |
| EBITDA |
| 63,535 |
|
| 64,114 |
|
| (26,931) |
|
| 100,718 |
| Add/(deduct): |
|
|
|
|
|
|
|
|
|
|
|
| Intercompany interest expense/(income) |
| (5,194) |
|
| (3,442) |
|
| 8,636 |
|
| - |
| Interest income |
| (29) |
|
| (22) |
|
| (4,192) |
|
| (4,243) |
| Stock option expense |
| - |
|
| - |
|
| 9,026 |
|
| 9,026 |
| Severance arrangement |
| - |
|
| - |
|
| 5,337 |
|
| 5,337 |
| Long-term incentive compensation |
| - |
|
| - |
|
| 3,784 |
|
| 3,784 |
| Adjusted EBITDA | $ | 58,312 |
| $ | 60,650 |
| $ | (4,340) |
| $ | 114,622 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Chemed | |
For the three months ended March 31, 2023 | VITAS |
| Roto-Rooter |
| Corporate |
| Consolidated | |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income/(loss) | $ | 24,764 |
| $ | 47,653 |
| $ | (18,296) |
| $ | 54,121 |
| Add/(deduct): |
|
|
|
|
|
|
|
|
|
|
|
| Interest expense |
| 50 |
|
| 133 |
|
| 1,368 |
|
| 1,551 |
| Income taxes |
| 8,515 |
|
| 15,275 |
|
| (6,746) |
|
| 17,044 |
| Depreciation |
| 4,958 |
|
| 7,312 |
|
| 16 |
|
| 12,286 |
| Amortization |
| 26 |
|
| 2,487 |
|
| - |
|
| 2,513 |
| EBITDA |
| 38,313 |
|
| 72,860 |
|
| (23,658) |
|
| 87,515 |
| Add/(deduct): |
|
|
|
|
|
|
|
|
|
|
|
| Intercompany interest expense/(income) |
| (4,648) |
|
| (2,743) |
|
| 7,391 |
|
| - |
| Interest income |
| (121) |
|
| (29) |
|
| - |
|
| (150) |
| Stock option expense |
| - |
|
| - |
|
| 8,482 |
|
| 8,482 |
| Long-term incentive compensation |
| - |
|
| - |
|
| 2,514 |
|
| 2,514 |
| Litigation settlements |
| - |
|
| 1,756 |
|
| - |
|
| 1,756 |
| Adjusted EBITDA | $ | 33,544 |
| $ | 71,844 |
| $ | (5,271) |
| $ | 100,117 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
RECONCILIATION OF ADJUSTED NET INCOME | ||||||
(in thousands, except per share data)(unaudited) | ||||||
|
|
|
|
|
|
|
| Three Months Ended March 31, |
| ||||
| 2024 |
| 2023 |
| ||
Net income as reported | $ | 65,017 |
| $ | 54,121 |
|
|
|
|
|
|
|
|
Add/(deduct) pre-tax cost of: |
|
|
|
|
|
|
Stock option expense |
| 9,026 |
|
| 8,482 |
|
Severance arrangement |
| 5,337 |
|
| - |
|
Long-term incentive compensation |
| 3,784 |
|
| 2,514 |
|
Amortization of reacquired franchise agreements |
| 2,352 |
|
| 2,352 |
|
Litigation settlements |
| - |
|
| 1,756 |
|
Add/(deduct) tax impacts: |
|
|
|
|
|
|
Tax impact of the above pre-tax adjustments (1) |
| (2,388) |
|
| (2,852) |
|
Excess tax benefits on stock compensation |
| (3,297) |
|
| (1,650) |
|
Adjusted net income | $ | 79,831 |
| $ | 64,723 |
|
|
|
|
|
|
|
|
Diluted Earnings Per Share As Reported |
|
|
|
|
|
|
Net income | $ | 4.24 |
| $ | 3.58 |
|
Average number of shares outstanding |
| 15,339 |
|
| 15,110 |
|
|
|
|
|
|
|
|
Adjusted Diluted Earnings Per Share |
|
|
|
|
|
|
Adjusted net income | $ | 5.20 |
| $ | 4.28 |
|
Adjusted average number of shares outstanding |
| 15,339 |
|
| 15,110 |
|
|
|
|
|
|
|
|
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated. |
|
|
|
|
|
|
|
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||
OPERATING STATISTICS FOR VITAS SEGMENT | ||||||
(unaudited) | ||||||
| Three Months Ended March 31, |
| ||||
OPERATING STATISTICS | 2024 |
| 2023 |
| ||
Net revenue ($000) |
|
|
|
|
|
|
Homecare | $ | 304,860 |
| $ | 267,050 |
|
Inpatient |
| 30,303 |
|
| 29,093 |
|
Continuous care |
| 24,169 |
|
| 19,941 |
|
Other |
| 4,084 |
|
| 3,021 |
|
Subtotal | $ | 363,416 |
| $ | 319,105 |
|
Room and board, net |
| (2,944) |
|
| (2,769) |
|
Contractual allowances |
| (4,090) |
|
| (3,108) |
|
Medicare cap allowance |
| (2,375) |
|
| (2,750) |
|
Total | $ | 354,007 |
| $ | 310,478 |
|
Net revenue as a percent of total before Medicare cap allowances |
|
|
|
|
|
|
Homecare |
| 83.9 | % |
| 83.7 | % |
Inpatient |
| 8.3 |
|
| 9.1 |
|
Continuous care |
| 6.7 |
|
| 6.2 |
|
Other |
| 1.1 |
|
| 1.0 |
|
Subtotal |
| 100.0 |
|
| 100.0 |
|
Room and board, net |
| (0.8) |
|
| (0.8) |
|
Contractual allowances |
| (1.1) |
|
| (1.0) |
|
Medicare cap allowance |
| (0.7) |
|
| (0.9) |
|
Total |
| 97.4 | % |
| 97.3 | % |
Days of care |
|
|
|
|
|
|
Homecare |
| 1,447,912 |
|
| 1,286,437 |
|
Nursing home |
| 283,158 |
|
| 265,429 |
|
Respite |
| 7,752 |
|
| 5,760 |
|
Subtotal routine homecare and respite |
| 1,738,822 |
|
| 1,557,626 |
|
Inpatient |
| 26,645 |
|
| 26,369 |
|
Continuous care |
| 24,037 |
|
| 20,686 |
|
Total |
| 1,789,504 |
|
| 1,604,681 |
|
|
|
|
|
|
|
|
Number of days in relevant time period |
| 91 |
|
| 90 |
|
|
|
|
|
|
|
|
Average daily census (days) |
|
|
|
|
|
|
Homecare |
| 15,911 |
|
| 14,294 |
|
Nursing home |
| 3,112 |
|
| 2,949 |
|
Respite |
| 85 |
|
| 64 |
|
Subtotal routine homecare and respite |
| 19,108 |
|
| 17,307 |
|
Inpatient |
| 293 |
|
| 293 |
|
Continuous care |
| 264 |
|
| 230 |
|
Total |
| 19,665 |
|
| 17,830 |
|
|
|
|
|
|
|
|
Total Admissions |
| 16,911 |
|
| 16,179 |
|
Total Discharges |
| 16,170 |
|
| 15,405 |
|
Average length of stay (days) |
| 103.9 |
|
| 99.9 |
|
Median length of stay (days) |
| 16.0 |
|
| 15.0 |
|
|
|
|
|
|
|
|
ADC by major diagnosis |
|
|
|
|
|
|
Cerebro |
| 43.6 | % |
| 41.8 | % |
Neurological |
| 13.4 |
|
| 19.3 |
|
Cancer |
| 10.1 |
|
| 10.5 |
|
Cardio |
| 16.1 |
|
| 16.0 |
|
Respiratory |
| 7.2 |
|
| 7.3 |
|
Other |
| 9.6 |
|
| 5.1 |
|
Total |
| 100.0 | % |
| 100.0 | % |
Admissions by major diagnosis |
|
|
|
|
|
|
Cerebro |
| 27.7 | % |
| 26.4 | % |
Neurological |
| 7.5 |
|
| 10.7 |
|
Cancer |
| 24.6 |
|
| 24.7 |
|
Cardio |
| 15.6 |
|
| 16.2 |
|
Respiratory |
| 10.8 |
|
| 10.9 |
|
Other |
| 13.8 |
|
| 11.1 |
|
Total |
| 100.0 | % |
| 100.0 | % |
|
|
|
|
|
|
|
Estimated uncollectible accounts as a percent of revenues |
| 1.1 | % |
| 1.0 | % |
Accounts receivable -- |
|
|
|
|
|
|
Days of revenue outstanding- excluding unapplied Medicare payments |
| 42.3 |
|
| 34.7 |
|
Days of revenue outstanding- including unapplied Medicare payments |
| 34.3 |
|
| 29.2 |
|
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Regarding Forward-Looking Information
Certain statements contained in this report are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe”, “expect”, “hope”, “anticipate”, “plan” and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. These forward-looking statements are based on current expectations and assumptions and involve various known and unknown risks, uncertainties, contingencies and other factors, which could cause Chemed’s actual results to differ from those expressed in such forward-looking statements. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. In addition, our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of projections and other financial matters. Investors are cautioned that such forward-looking statements are subject to inherent risk and there are no assurances that the matters contained in such statements will be achieved. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
The Company’s primary market risk exposure relates to interest rate risk exposure through its variable interest line of credit. At March 31, 2024, the Company had no variable rate debt outstanding. For each $10 million borrowed under the credit facility, an increase or decrease of 100 basis points (1%), increases or decreases the Company’s annual interest expense by $100,000.
The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.
Item 4. Controls and Procedures
We carried out an evaluation, under the supervision of the Company’s President and Chief Executive Officer and with the participation of the Vice President, Chief Financial Officer and Controller, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, the President and Chief Executive Officer and Vice President, Chief Financial Officer and Controller have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report. There has been no change in our internal control over financial reporting that occurred during the quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
For information regarding the Company’s legal proceedings, see Note 10, Legal and Regulatory Matters, under Part I, Item I of this Quarterly Report on Form 10-Q.
Item 1A. Risk Factors
There have been no other material changes from the risk factors previously disclosed in the Company’s most recent Annual Report on Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 2(c). Purchases of Equity Securities by Issuer and Affiliated Purchasers
The following table shows the activity related to our share repurchase program for the first three months of 2024:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total Number |
| Weighted Average |
| Cumulative Shares |
| Dollar Amount | ||
| of Shares |
| Price Paid Per |
| Repurchased Under |
| Remaining Under | ||
| Repurchased |
| Share |
| the Program |
| The Program | ||
|
|
|
|
|
|
|
|
|
|
February 2011 Program |
|
|
|
|
|
|
|
|
|
January 1 through January 31, 2024 | - |
| $ | - |
| 10,591,123 |
| $ | 314,054,431 |
February 1 through February 29, 2024 | - |
|
| - |
| 10,591,123 |
|
| 314,054,431 |
March 1 through March 31, 2024 | 50,000 |
|
| 646.87 |
| 10,641,123 |
| $ | 281,710,685 |
|
|
|
|
|
|
|
|
|
|
First Quarter Total | 50,000 |
| $ | 646.87 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
None.
Item 6. Exhibits
|
|
|
|
|
|
Exhibit No. |
| Description |
|
|
|
| Certification by Kevin J. McNamara pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934. | |
|
|
|
|
|
|
| ||
|
|
|
| Certification by Kevin J. McNamara pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
|
|
|
|
|
|
| Certification by Michael D. Witzeman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | |
|
|
|
101 |
| The following materials from Chemed Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) The Condensed Consolidated Balance Sheet, (ii) The Condensed Consolidated Statement of Income, (iii) The Condensed Consolidated Statement of Cash Flows, (iv) The Condensed Statement of Equity, and (v) Notes to the Condensed Consolidated Financial Statements. |
104 |
| The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in iXBRL and contained in Exhibit 101. |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
| Chemed Corporation |
|
|
|
|
|
| (Registrant) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: |
| April 29, 2024 |
| By: |
| /s/ Kevin J. McNamara |
|
|
|
|
|
| Kevin J. McNamara |
|
|
|
|
|
| (President and Chief Executive Officer) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dated: |
| April 29, 2024 |
| By: |
| /s/ Michael D. Witzeman |
|
|
|
|
|
| Michael D. Witzeman |
|
|
|
|
|
| (Vice President, Chief Financial Officer and Controller) |
EXHIBIT 31.1
CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934
I, Kevin J. McNamara, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Chemed Corporation (“registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. |
The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors or persons performing the equivalent function: |
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
|
Date: April 29, 2024 |
|
/s/ Kevin J. McNamara |
|
|
Kevin J. McNamara |
|
|
(President and Chief Executive Officer) |
|
|
|
E-6
EXHIBIT 31.2
CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934
I, Michael D. Witzeman, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Chemed Corporation (“registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors or persons performing the equivalent function:
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
|
|
|
|
Date: April 29, 2024 |
|
/s/ Michael D. Witzeman |
|
|
Michael D. Witzeman |
|
|
(Vice President, Controller, and Chief Financial Officer) |
E-2
EXHIBIT 32.1
CERTIFICATION BY KEVIN J. MCNAMARA
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as President and Chief Executive Officer of Chemed Corporation (“Company”), does hereby certify that:
1) the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2024 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
Date: April 29, 2024 |
|
/s/ Kevin J. McNamara |
|
|
Kevin J. McNamara |
|
|
(President and Chief Executive Officer) |
|
|
|
E-4
EXHIBIT 32.2
CERTIFICATION BY MICHAEL D. WITZEMAN
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002.
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Executive Vice President and Chief Financial Officer of Chemed Corporation (“Company”), does hereby certify that:
1) the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2024 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
|
Date: April 29, 2024 |
|
/s/ Michael D. Witzeman |
|
|
Michael D. Witzeman |
|
|
(Vice President, Controller and Chief Financial Officer) |
E-5